Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 6Other neoplasm 1

Conditions

Skin Diseases 1Precancerous Conditions 1Keratosis, Actinic 1Keratosis 1

Interventions

Gemcitabine 2Aminolevulinic Acid 2toripalimab 1tirbanibulin 1ruxolitinib 1potassium oxonate 1penpulimab 1human papillomavirus vaccine, L1 type 16, 18 1gimeracil 1apatinib 1Watchful Waiting 1Transurethral Resection of Prostate 1Toremifene 1Tegafur 1Robotic Surgical Procedures 1Rifampin 1RAD140 1Pregnancy Tests 1Pemetrexed 1ON 01910 1Nivolumab 1Itraconazole 1Irinotecan 1Injections 1Infusions, Intravenous 1Hysterectomy 1Human Papillomavirus DNA Tests 1High-Intensity Focused Ultrasound Ablation 1Excipients 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × BF-200 ALA × Other neoplasm × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡